Abrogation of Estrogen Receptor Signaling Augments Cytotoxicity of Anticancer Drugs on CaSki Cervical Cancer Cells

Overview

Journal Anticancer Res

Specialty Oncology

Date 2008 Aug 30

PMID 18751393

Citations 3

Authors

Moon Y Heo

Salama A Salama

Nilufar Khatoon

Ayman Al-Hendy

William W Au

Affiliations

Soon will be listed here.

Abstract

Background: We have reported that a gene therapy approach, using a dominant-negative estrogen receptor blocker (DN) gene, can cause cell death in cervical cancer cells in vitro. We investigated the mechanisms for enhanced cell killing when DN was combined with cisplatin (CP) and paclitaxel (TX).

Materials And Methods: Cells were transduced with DN at 24 h and/or treated with drugs at 48 h, and harvested at 48 and 72 h after transduction. Effects were determined using the MTT cytotoxic, and TUNEL and caspase-3 activity apoptotic assays.

Results: Each agent induced cytotoxic and apoptotic effects, and activated caspase-3. In the combined treatments, significant synergistic effects were observed based on the MTT and TUNEL assays, but with antagonistic caspase-3 activation effect.

Conclusion: The enhanced cell killing effect was mediated by the initiation of new and multiple mechanisms, particularly via caspase-independent pathways.

Citing Articles

Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.

Drakopoulou E, Anagnou N, Pappa K Cancers (Basel). 2022; 14(13).

PMID: 35805007 PMC: 9265289. DOI: 10.3390/cancers14133238.

Targeted Gene Delivery Therapies for Cervical Cancer.

Ayen A, Jimenez Martinez Y, Boulaiz H Cancers (Basel). 2020; 12(5).

PMID: 32455616 PMC: 7281413. DOI: 10.3390/cancers12051301.

Raloxifene suppress proliferation-promoting function of estrogen in CaSKi cervical cells.

Ma J, Wang X, Tang L, Chen X, Lou G Int J Clin Exp Med. 2015; 8(4):5571-5.

PMID: 26131140 PMC: 4483908.

References

Zhang W, Zhang C, Narayani N, Du C, Balaji K . Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells. Cancer Lett. 2007; 255(1):127-34. DOI: 10.1016/j.canlet.2007.04.006. View

Arbeit J, Howley P, Hanahan D . Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A. 1996; 93(7):2930-5. PMC: 39737. DOI: 10.1073/pnas.93.7.2930. View

Au W, Abdou-Salama S, Sierra-Torres C, Al-Hendy A . Environmental risk factors for prevention and molecular intervention of cervical cancer. Int J Hyg Environ Health. 2006; 210(6):671-678. DOI: 10.1016/j.ijheh.2006.10.003. View

Garcia-Lopez P, Rodriguez-Dorantes M, Perez-Cardenas E, Cerbon M, Mohar-Betancourt A . Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines. Cancer Chemother Pharmacol. 2004; 53(6):533-40. DOI: 10.1007/s00280-003-0760-3. View

Pyeon D, Newton M, Lambert P, den Boon J, Sengupta S, Marsit C . Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 2007; 67(10):4605-19. PMC: 2858285. DOI: 10.1158/0008-5472.CAN-06-3619. View

Kim R . Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer. 2005; 103(8):1551-60. DOI: 10.1002/cncr.20947. View

Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K . BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol. 2007; 178(2):283-96. PMC: 2064447. DOI: 10.1083/jcb.200702134. View

Rudolf E, Rudolf K, Cervinka M . Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol. 2007; 24(2):123-41. DOI: 10.1007/s10565-007-9022-1. View

Lee K, Yim E, Kim C, Namkoong S, Um S, Park J . Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005; 98(1):45-53. DOI: 10.1016/j.ygyno.2005.04.010. View

10.

Zamble D, Mu D, Reardon J, Sancar A, Lippard S . Repair of cisplatin--DNA adducts by the mammalian excision nuclease. Biochemistry. 1996; 35(31):10004-13. DOI: 10.1021/bi960453+. View

11.

Sacks P, Harris D, Chou T . Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer. 1995; 61(3):409-15. DOI: 10.1002/ijc.2910610322. View

12.

Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C . Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem. 2007; 304(1-2):315-23. DOI: 10.1007/s11010-007-9514-6. View

13.

Judson P, Watson J, Gehrig P, Fowler Jr W, Haskill J . Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res. 1999; 59(10):2425-32. View

14.

Brake T, Lambert P . Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A. 2005; 102(7):2490-5. PMC: 548999. DOI: 10.1073/pnas.0409883102. View

15.

Pereira F, Mudgil A, Rosmarin D . Toxic epidermal necrolysis. J Am Acad Dermatol. 2007; 56(2):181-200. DOI: 10.1016/j.jaad.2006.04.048. View

16.

Smith J, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M . Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003; 361(9364):1159-67. DOI: 10.1016/s0140-6736(03)12949-2. View

17.

Au W, Abdou-Salama S, Al-Hendy A . Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor gene. Gynecol Oncol. 2006; 104(2):276-80. PMC: 1831876. DOI: 10.1016/j.ygyno.2006.10.015. View

18.

Chou T . Drug combinations: from laboratory to practice. J Lab Clin Med. 1998; 132(1):6-8. DOI: 10.1016/s0022-2143(98)90018-x. View

19.

Oshima Y, Sasaki Y, Negishi H, Idogawa M, Toyota M, Yamashita T . Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines. Cancer Biol Ther. 2007; 6(7):1058-66. DOI: 10.4161/cbt.6.7.4320. View

20.

Davis J, Desoto J, Fryar E, Southerland W, Bowen D . Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection. Cell Mol Biol (Noisy-le-grand). 2007; 53(3):18-26. View